stoxline Quote Chart Rank Option Currency Glossary
  
Incyte Corporation (INCY)
65.3  1.3 (2.03%)    07-17 16:00
Open: 63.96
High: 65.34
Volume: 1,665,272
  
Pre. Close: 64
Low: 63.51
Market Cap: 14,683(M)
Technical analysis
2024-07-17 5:28:10 PM
Short term     
Mid term     
Targets 6-month :  76.31 1-year :  89.13
Resists First :  65.33 Second :  76.31
Pivot price 61.18
Supports First :  60.03 Second :  56.75
MAs MA(5) :  63.9 MA(20) :  61.57
MA(100) :  57.71 MA(250) :  59
MACD MACD :  1.1 Signal :  0.7
%K %D K(14,3) :  95.8 D(3) :  92.8
RSI RSI(14): 68.3
52-week High :  67.36 Low :  50.27
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ INCY ] has closed below upper band by 6.4%. Bollinger Bands are 83.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 65.41 - 65.67 65.67 - 65.9
Low: 62.8 - 63.12 63.12 - 63.39
Close: 64.74 - 65.27 65.27 - 65.72
Company Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Headline News

Wed, 17 Jul 2024
Barry P. Flannelly Sells 1,306 Shares of Incyte Co. (NASDAQ:INCY) Stock - MarketBeat

Wed, 17 Jul 2024
Russell Investments Group Ltd. Has $58.90 Million Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat

Wed, 17 Jul 2024
Is Incyte Corporation's (NASDAQ:INCY) Recent Stock Performance Tethered To Its Strong Fundamentals? - Yahoo Finance

Tue, 16 Jul 2024
Are Strong Financial Prospects The Force That Is Driving The Momentum In Incyte Corporation's NASDAQ:INCY) Stock? - Simply Wall St

Mon, 15 Jul 2024
Incyte (INCY) Gains 19.6% in Three Months: Here's Why - Nasdaq

Mon, 15 Jul 2024
Mutual of America Capital Management LLC Has $1.39 Million Holdings in Incyte Co. (NASDAQ:INCY) - American Banking and Market News

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 197 (M)
Shares Float 192 (M)
Held by Insiders 1.7 (%)
Held by Institutions 97.1 (%)
Shares Short 18,720 (K)
Shares Short P.Month 7,540 (K)
Stock Financials
EPS 3.29
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 24.02
Profit Margin 19.7 %
Operating Margin 10.4 %
Return on Assets (ttm) 6.8 %
Return on Equity (ttm) 15.1 %
Qtrly Rev. Growth 8.8 %
Gross Profit (p.s.) 0
Sales Per Share 19.13
EBITDA (p.s.) 4.06
Qtrly Earnings Growth 670.5 %
Operating Cash Flow 821 (M)
Levered Free Cash Flow 978 (M)
Stock Valuations
PE Ratio 19.78
PEG Ratio 0.5
Price to Book value 2.71
Price to Sales 3.41
Price to Cash Flow 15.67
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android